Want to see TSE:MDP full AI Analyst Report?
Top Page
Medexus Pharmaceuticals Inc
(TSX:MDP)
Select Model
Select Model
Rating:61Neutral
Price Target:
C$5.50
▲(38.54% Upside)
Action:Reiterated
Date:07/01/26
The score is driven primarily by moderate financial performance: improved leverage and solid operating cash flow are meaningful strengths, but they are tempered by 2026 revenue decline, renewed net losses, and weaker free-cash-flow conversion. Technicals add support with the stock trading above major moving averages. Valuation remains a headwind due to a negative P/E and no provided dividend yield. Earnings-call commentary is constructive on GRAFAPEX growth guidance and traction, but near-term liquidity and legacy-product pressures keep the outlook mixed.
Positive Factors
Deleveraging / Balance sheet health
Medexus has materially reduced leverage versus prior years, lowering financial risk and interest sensitivity. A healthier capital structure provides durable flexibility to fund commercialization, absorb operational volatility, and negotiate financing on better terms over the next several quarters.
Negative Factors
Revenue decline and portfolio disruption
Revenue fell due to loss of legacy product revenue and generic competition, exposing dependence on older assets. This transition creates near-term top-line pressure and visibility challenges until new products like GRAFAPEX scale, leaving a 2–6 month risk window for sustained growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging / Balance sheet health
Medexus has materially reduced leverage versus prior years, lowering financial risk and interest sensitivity. A healthier capital structure provides durable flexibility to fund commercialization, absorb operational volatility, and negotiate financing on better terms over the next several quarters.
Read all positive factors
Medexus Pharmaceuticals Inc (MDP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$162.42M
Dividend YieldN/A
Average Volume (3M)46.68K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-8.88%
EPS Growth-179.75%
CountryCA
Employees90
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.07
Shares Outstanding31,660,482
10 Day Avg. Volume30,861
30 Day Avg. Volume46,683
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.06
Price to Sales (P/S)1.02
P/FCF Ratio27.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.00Price Target Upside51.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.25
Revenue Forecast (FY)C$114.53M
Medexus Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary...
How the Company Makes Money
Medexus primarily makes money by generating revenue from the sale of its specialty pharmaceutical products in the markets where it holds commercialization rights. Its core revenue stream is product sales to customers (e.g., wholesalers, hospitals,...
Medexus Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:Jun 25, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
The call was mixed. Operationally and strategically the company presented several clear positives: GRAFAPEX is showing early commercial traction and cash-generation, Q4 showed improved adjusted EBITDA and operating income, gross margins improved, and management secured a strategic BD asset (UM171) aligned with a focused HSCT strategy. However, fiscal-year comparisons highlight meaningful headwinds: a ~8.3% decline in revenue year-over-year, an ~18.3% drop in adjusted EBITDA on an annual basis, a swing to net loss, and a sharp decline in cash on hand driven by a $15M milestone payment. The outlook centers on confidence in GRAFAPEX to drive growth (guidance $30M–$32M in FY2027) and a shift toward HSCT-focused BD, but near-term financial metrics reflect a transitional year with liquidity and legacy-product pressures.Positive Updates
GRAFAPEX Achieves Cash-Flow Accretion and Strong Early Traction
Product-level performance for GRAFAPEX was accretive to quarterly operating cash flows in fiscal Q4 2026. For the 12 months ended March 31, 2026, GRAFAPEX generated $11.6M of product-level net revenue, exceeding the $11.2M invested in the launch over the same period. Management expects GRAFAPEX to generate $30M–$32M in fiscal 2027 and to exceed $100M in annual product-level net revenue within five years of launch.
Negative Updates
Fiscal Year Revenue Decline
Fiscal 2026 net revenue was $99.3M, down $9.0M or approximately -8.3% from $108.3M in fiscal 2025. The decline primarily reflects reduced product-level revenue from Gleolan in the U.S. following the March 2025 termination of the U.S. Gleolan agreement and generic competition for Rupall in Canada.
Read all updates
Q4-2026 Updates
Positive
Negative
GRAFAPEX Achieves Cash-Flow Accretion and Strong Early Traction
Product-level performance for GRAFAPEX was accretive to quarterly operating cash flows in fiscal Q4 2026. For the 12 months ended March 31, 2026, GRAFAPEX generated $11.6M of product-level net revenue, exceeding the $11.2M invested in the launch over the same period. Management expects GRAFAPEX to generate $30M–$32M in fiscal 2027 and to exceed $100M in annual product-level net revenue within five years of launch.
Read all positive updates
Company Guidance
Management guided GRAFAPEX to product-level net revenue of $30–32 million for fiscal 2027 (with management noting ~50% sequential quarter-over-quarter growth and some seasonality: softer in July/August and December), and reiterated a target to exceed $100 million of annual product-level net revenue within five years of launch; this builds on FY2026 GRAFAPEX product-level net revenue of $11.6M (which exceeded $11.2M of launch investment over the same 12 months), with 74 of 180 U.S. transplant centers having ordered (54 have reordered), coverage of >200 million lives and 42 commercial plans with coverage pathways, wholesaler inventory around 1–1.5 months, and patient-level use of ~$3.9M versus quarterly GRAFAPEX revenue of $3.4M in the quarter referenced. Management expects GRAFAPEX-specific SG&A of $3–4M in FY2027, a modest increase in overall SG&A, incremental R&D spend, and that GRAFAPEX will drive growth in operating cash flow after FY2026 operating cash flow of $18.9M (Q4 operating cash flow $3.8M; average $4.2M per quarter since launch); company liquidity and leverage at Mar 31, 2026: cash $6.5M, debt $22.4M, and net debt / adjusted EBITDA 0.95 (adjusted EBITDA FY2026 $16.5M).Medexus Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
53
Neutral
Balance Sheet
62
Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2026 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 99.33M | 108.33M | 108.10M | 76.70M | 79.66M |
| Gross Profit | 54.41M | 56.58M | 60.04M | 37.93M | 42.01M |
| EBITDA | 12.66M | 16.81M | 14.65M | 14.55M | -23.61M |
| Net Income | -2.39M | 2.25M | 1.22M | -2.88M | -28.26M |
Balance Sheet | |||||
| Total Assets | 147.28M | 171.84M | 161.33M | 139.22M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 6.52M | 23.97M | 13.07M | 10.02M | 18.70M |
| Total Debt | 22.26M | 37.18M | 70.08M | 54.86M | 44.87M |
| Total Liabilities | 98.29M | 119.69M | 138.88M | 121.43M | 130.50M |
| Stockholders Equity | 48.99M | 52.14M | 22.45M | 17.79M | 18.02M |
Cash Flow | |||||
| Free Cash Flow | 3.72M | 21.31M | -1.81M | -8.89M | -5.72M |
| Operating Cash Flow | 18.87M | 24.03M | -1.44M | -1.18M | 5.04M |
| Investing Cash Flow | -17.40M | -6.00M | -1.72M | -8.20M | -11.70M |
| Financing Cash Flow | -18.92M | 796.00K | 6.41M | 663.00K | 18.68M |
Medexus Pharmaceuticals Inc Technical Analysis
Positive
3.97
Price Trends
4.25
Positive
3.85
Positive
3.31
Positive
Market Momentum
0.30
Negative
68.37
Neutral
75.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Positive. The current price of 3.97 is below the 20-day moving average (MA) of 4.67, below the 50-day MA of 4.25, and above the 200-day MA of 3.31, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 68.37 is Neutral, neither overbought nor oversold. The STOCH value of 75.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MDP.
Medexus Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | C$167.00M | 18.02 | 22.05% | 1.60% | 20.13% | 17.08% | |
61 Neutral | C$162.42M | -47.34 | -0.52% | ― | -8.88% | -179.75% | |
52 Neutral | C$61.92M | -2.27 | -21.73% | ― | 31.50% | 17.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$25.13M | -6.92 | -256.01% | ― | ― | -28.29% | |
43 Neutral | C$11.17M | -1.66 | -18.39% | ― | 44.34% | -281.74% | |
41 Neutral | C$46.80M | -4.85 | ― | ― | -62.34% | 9.80% |
* Healthcare Sector Average
TSE:MDP
Medexus Pharmaceuticals Inc
5.15
2.33
82.62%
TSE:MPH
Medicure
1.07
-0.04
-3.60%
TSE:RX
Biosyent
14.60
3.37
30.01%
TSE:VEXT
Vext Science
0.25
0.08
47.06%
TSE:VM
Voyageur Pharmaceuticals
0.14
-0.05
-28.95%
TSE:BNXT
BioNxt Solutions
0.37
-0.21
-36.21%
Medexus Pharmaceuticals Inc Corporate Events
Business Operations and StrategyStock BuybackProduct-Related Announcements
Medexus Advances U.S. GRAFAPEX Rollout While Streamlining Capital Structure
Positive
Apr 15, 2026
Medexus Pharmaceuticals reported continued progress in the U.S. commercialization of GRAFAPEX, with 56 transplant centers granting formulary inclusion and 64 centers placing orders as of March 31, 2026. Management said these adoption metrics align...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.